A Plus Biotechnology Co (TPE:6918) ROCE %: 16.53% (As of Dec. 2025)


TPE:6918 A Plus Biotechnology Co Ltd TPE:6918
71 GF Score
Price NT$74.30
GF Value NT$87.15
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is A Plus Biotechnology Co ROCE %?

A Plus Biotechnology Co TPE:6918 -1.59% 71 ROCE % is 16.53% as of Dec. 2025. GuruFocus rates TPE:6918 with a GF Score™ of 71/100 and a GF Value™ of NT$87.15 (Modestly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. A Plus Biotechnology Co's annualized ROCE % for the quarter that ended in Dec. 2025 was 16.53%.

A Plus Biotechnology Co  (TPE:6918) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

A Plus Biotechnology Co ROCE % Related Terms

A Plus Biotechnology Co ROCE % Historical Data

* Premium members only.

The historical data trend for A Plus Biotechnology Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A Plus Biotechnology Co ROCE % Chart

A Plus Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial 5.42 7.06 0.60 19.54 18.45

A Plus Biotechnology Co Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.66 22.23 19.72 16.31 16.53
TPE:6918
71GF Score
A Plus Biotechnology Co Ltd TPE:6918
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

A Plus Biotechnology Co ROCE % Calculation

A Plus Biotechnology Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=218.309/( ( (1177.314 - 163.309) + (1549.999 - 198.133) )/ 2 )
=218.309/( (1014.005+1351.866)/ 2 )
=218.309/1182.9355
=18.45 %

A Plus Biotechnology Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=222.644/( ( (1528.881 - 187.694) + (1549.999 - 198.133) )/ 2 )
=222.644/( ( 1341.187 + 1351.866 )/ 2 )
=222.644/1346.5265
=16.53 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 16.53% mean?
A Plus Biotechnology Co (TPE:6918) has a ROCE % of 16.53% as of Dec. 2025.
Is A Plus Biotechnology Co's ROCE % too high?
A Plus Biotechnology Co's current ROCE % is 16.53%. The Medical Devices & Instruments industry median ROCE % is 2.20. A Plus Biotechnology Co's value of 16.53% is 651.4% above this industry median. Overall, A Plus Biotechnology Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's ROCE % compare to ABT and SYK?
A Plus Biotechnology Co's ROCE % of 16.53% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.20. A Plus Biotechnology Co's value of 16.53% is 651.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.20, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. A Plus Biotechnology Co's current ROCE % of 16.53% is 651.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. A Plus Biotechnology Co's current ROCE % is 16.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.15, compared to a current price of NT$74.30 — trading 14.7% below its estimated fair value. The current ROCE % is 16.53% and 651.4% above the Medical Devices & Instruments industry median of 2.20. A Plus Biotechnology Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current ROCE % is 16.53% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?

Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued. The current stock price of NT$74.30 is trading 14.7% below its estimated GF Value™ of NT$87.15. GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.

Key valuation signals for TPE:6918:

  • ROCE %: 16.53%
  • GF Value™: NT$87.15 vs. price of NT$74.30 (14.7% below fair value)
  • GF Score™: 71/100 with 3 warning signs
  • Industry Position: 651.4% above the Medical Devices & Instruments median

No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

A Plus Biotechnology Co Business Description

Address No. 21, Qiaohe Road, 3rd Floor, Zhonghe District, New Taipei City, TWN
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
71GF Score

Get the complete analysis for TPE:6918

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$74.30
Price
NT$87.15
GF Value